EEF2K and breast cancer: The key observations were increased AKT signaling in PTEN/p53-deficient tumors, and the results of the kinome drug screen performed on tumor cultures from one MMTV-Cre:PTENf/f:p53f/f tumor and two human breast cancer cell lines [one basal-like and one claudin-low (Prat et al, 2010)] with 238 compounds where the top hit was an inhibitor of eukaryotic Elongation Factor-2 kinase (eEF2K), followed by a c-Jun N-terminal Kinase (JNK) inhibitor.